These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32002559)

  • 1. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Matsuda Y; Sakuma K; Iwata N
    Psychopharmacology (Berl); 2020 May; 237(5):1459-1470. PubMed ID: 32002559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
    Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
    Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
    Antoun Reyad A; Girgis E; Mishriky R
    Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexpiprazole: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
    Aladeen T; Westphal E; Lee Y; Rong C; Rainka M; Capote H; McIntyre RS
    Perspect Psychiatr Care; 2018 Oct; 54(4):507-513. PubMed ID: 29427512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brexpiprazole for treatment of schizophrenia: a critical literature study].
    Spoelstra SK; Baas CAJ; Knegtering H
    Tijdschr Psychiatr; 2021; 63(1):48-55. PubMed ID: 33537974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis.
    Kishi T; Sakuma K; Saito T; Nakagawa A; Kato M; Iwata N
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):165-175. PubMed ID: 38219278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
    Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.
    Ng-Mak D; Tongbram V; Ndirangu K; Rajagopalan K; Loebel A
    J Comp Eff Res; 2018 Aug; 7(8):737-748. PubMed ID: 29697278
    [No Abstract]   [Full Text] [Related]  

  • 20. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
    Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.